Please login to the form below

Not currently logged in
Email:
Password:

Actos

This page shows the latest Actos news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

Piogliazone is sold by Takeda under the Actos brand and was a $4bn-a-year product before losing patent protection in 2011, after which generic versions entered the market.

Latest news

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    The new guidance allows the drugs to be used first-line for people who cannot tolerate metformin, and in whom sulfonylureas or Takeda's Actos (pioglitazone) are not considered appropriate.

  • Takeda to pay $2.4bn to settle Actos cancer suits Takeda to pay $2.4bn to settle Actos cancer suits

    Actos (pioglitazone) is licensed to help patients with type II diabetes reduce their sugar levels and has been on the market for more than 15 years. ... Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but

  • US judge cuts billions from Takeda/Lilly Actos payment US judge cuts billions from Takeda/Lilly Actos payment

    The case is one of thousands consolidated in US courts that claim Takeda and Lilly deliberately misled regulators about a link between type 2 diabetes drug Actos and bladder cancer. ... Takeda has set up six trials involving Actos to help support the drug

  • Takeda loses in lawsuit claiming cancer link to Actos Takeda loses in lawsuit claiming cancer link to Actos

    Actos was a huge commercial success for Takeda, with sales peaking at $4.5bn before losing patent protection in the US in 2012. ... Court documents obtained by Bloomberg suggest Actos has generated more than $16bn in sales since its US launch in 1999.

  • Takeda: No link between Actos and bladder cancer Takeda: No link between Actos and bladder cancer

    Concerns were raised several years ago about Actos' potential to increase the risk of bladder cancer, leading to the withdrawal of the drug in France and Germany and the launch of ... statistically significant increased risk of developing bladder cancer

More from news
Approximately 6 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Ulcer drug lansoprazole and prostate cancer treatment leuprorelin already faced generic competition and before the deal was completed Takeda's diabetes drug Actos (pioglitazone) lost exclusivity in January 2011. ... German authorities quickly followed

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    to its multi-billion dollar main product, the antidiabetic Actos (pioglitazone), in August. ... Actos was withdrawn from the market in Germany and France, but not in the US.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics